The following article features coverage from the American Society of Clinical Oncology 2019 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

CHICAGO — Enterade® adherence for diarrhea prevention was a challenge for patients undergoing autologous stem cell transplantation (ASCT) for multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), according to results of a phase 2, multicenter, double-blinded, 2-arm randomized trial (ClinicalTrials.gov Identifier: NCT02919670). These findings were presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Enterade is a proprietary blend of 5 amino-acids and electrolytes that can facilitate retention of the absorbing capacity of the small intestine and was found to improve survival and body weight following irradiation in a mouse study.

Related Articles

The researchers enrolled 114 patients who were randomly assigned to receive either two 8-ounce bottles/day of enterade or placebo starting on the day of admission through day +14. Adherence was determined to be an immediate issue for many patients, and although 99 patients (61 with multiple myeloma, 38 with non-Hodgkin lymphoma) tried to consume at least 1 dose of either treatment, no patients with multiple myeloma and only 34.2% of patients with non-Hodgkin lymphoma adhered to the treatment.

Patients with non-Hodgkin lymphoma were relatively equally compliant in the enterade group (31.6%) and the placebo group (36.8%). When analyzing the primary end point among the patients with non-Hodgkin lymphoma, patients who received enterade and were compliant showed a 16% incidence of grade 2 or higher diarrhea compared with 86% of patients in the placebo group (P =.02).

“Eleven days of two 8 oz bottles of liquid is a difficult task during ASCT, especially for [patients with multiple myeloma] with nausea, altered taste, and poor appetite,” the authors wrote. Despite these challenges, the researchers feel that enterade warrants further study for the prevention of diarrhea after high-dose chemotherapy in populations who may be more amenable to oral agents.

Disclosure: Multiple authors declared affiliations with industry. Please refer to the original abstract for a full list of disclosures.

Read more of Cancer Therapy Advisor‘s coverage of ASCO’s annual meeting by visiting the conference page.

Reference

Luque L, Soiffer R, Glotzbecker B, et al. A phase II, double-blinded, randomized study using a proprietary amino acid mixture as diarrhea prevention in patients undergoing autologous stem cell transplantation (AST) for multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). Poster presentation at: 2019 ASCO Annual Meeting; May 31 to June 4, 2019; Chicago, IL. Abstract 11607.

This article originally appeared on Oncology Nurse Advisor